Why the study?
DOX-based chemotherapy causes severe systemic side effects, prompting the exploration of strategies such as nanocarriers, conjugates, structural modifications, immunotherapy, and combination therapy to improve efficacy and safety.
Design
Review
Authors
Loading...
Clinicians should await dedicated trials before using advanced doxorubicin formulations; leaves open their net benefit in cancer therapy.
Advanced formulations of doxorubicin, including nanocarriers and conjugates, require clinical trials to improve efficacy and safety in cancer chemotherapy.
Sohail et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: